Back

Kailera reports 16.0% weight loss for KAI-4729 in Phase 1 obesity study

Verifying
  • Kailera presented Phase 1 ribupatide injection-site data at the EASD 62nd Annual Meeting.
  • KAI-4729 produced up to 16.0% mean weight loss after 12 weeks in 10 participants.
  • Kailera plans KAI-4729's outside-China Phase 1 trial in 2026, with data expected in 2027.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.